Speaker: Naval Daver

0:16:47

Naval Daver - Immune antibodies and Cellular therapies in AML

0:28:44

6. The Burden of AML - Mutations and Prognostic Implications, Dr. Naval Daver

0:02:17

Naval Daver on SOHO Italy 2020

0:17:22

Naval Daver - Mutation Profiling of AML Patients

0:18:58

Naval Daver - FLT3 mutations in AML

0:10:25

Naval Daver - Pivekimab sunirine (PVEK, IMGN632) triplet with Azacitidine and Venetoclax

0:02:38

FLT3 inhibitors: revolutionizing the management of AML

0:02:12

Updates in AML research from MD Anderson: novel venetoclax combinations with Naval

0:02:02

Unmet needs in high-risk MDS and future therapeutic strategies

0:02:04

Emerging therapies in AML: why patients should be optimistic

1:49:00

Acute myeloblastic leukemia - How do I manage in 2022? by Dr. Naval Daver, USA

0:09:55

Immune checkpoint inhibitors in acute leukemia

0:04:54

Emerging immunotherapies for AML

0:04:17

AML: genetic screening and subtypes

0:02:07

ADCs for AML: gemtuzumab ozogamicin

0:02:44

Phase I/II study of novel FLT3 inhibitor HM43239 in R/R AML

0:04:55

Checkpoint inhibitor combination approaches for AML/MDS: an update

0:01:13

The importance of CD47 as a target in MDS and AML

0:06:44

Checkpoint inhibitor advances in AML

0:03:53

Investigating the combination of pivekimab sunirine, azacitidine & venetoclax in R/R AML

0:01:28

CD47 antibodies for the treatment of AML and MDS: where is the field moving?

0:59:51

Pathology Insights on Innovation in AML

0:07:40

Immunotherapy for AML and ALL: checkpoint inhibitors & CAR T-cells for B-cell ALL

0:01:40

The role of menin inhibitors in the treatment of AML